Want to see FR:LBIRD full AI Analyst Report?
Top Page
Lumibird SA
(LBIRD)
Select Model
Select Model
Rating:52Neutral
Price Target:
€23.00
▼(-8.55% Downside)
Action:Reiterated
Date:08/30/26
The score is driven primarily by decent fundamentals (steady revenue growth and improved 2025 profitability with manageable leverage) but is held back by inconsistent cash-flow/FCF history. Technical indicators add further pressure (price below key moving averages and negative MACD), and valuation is a headwind due to the high P/E despite a modest dividend yield.
Positive Factors
Steady Revenue Growth
Steady revenue expansion indicates continued demand for Lumibird’s photonics products across industrial, defense, and life-science applications. Although growth has moderated recently, a positive multi-year trend supports business scale, customer adoption, and the potential for sustained operating leverage.
Negative Factors
Inconsistent Cash Generation
Volatile free cash flow reduces confidence that reported earnings will consistently translate into funds available for investment, debt reduction, or shareholder returns. Weak conversion may reflect working-capital swings or capital intensity, leaving cash generation less dependable over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Steady revenue expansion indicates continued demand for Lumibird’s photonics products across industrial, defense, and life-science applications. Although growth has moderated recently, a positive multi-year trend supports business scale, customer adoption, and the potential for sustained operating leverage.
Read all positive factors
Lumibird SA (LBIRD) vs. iShares MSCI France ETF (EWQ)
Market Cap
€519.28M
Dividend Yield1.59%
Average Volume (3M)30.58K
Price to Earnings (P/E)36.9
Beta (1Y)0.51
Revenue Growth8.13%
EPS Growth31.36%
CountryFR
Employees1,078
SectorGeneral
Sector StrengthN/A
IndustryHardware, Equipment & Parts
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,466,883
10 Day Avg. Volume39,244
30 Day Avg. Volume30,578
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)2.31
Price to Sales (P/S)2.08
P/FCF Ratio37.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lumibird SA Business Overview & Revenue Model
Company Description
A global leader, Lumibird S.A. specializes in the development, manufacturing, and distribution of a wide array of laser technologies. Its sophisticated laser products are deployed worldwide across scientific, industrial, and medical sectors. The c...
How the Company Makes Money
Lumibird makes money primarily by selling photonics hardware and related solutions to customers in industry, defense, and healthcare/life-science markets. Key revenue streams generally include: (1) Product sales of laser sources and laser subsyste...
Lumibird SA Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
61
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 236.41M | 228.53M | 210.06M | 206.55M | 194.29M | 162.47M |
| Gross Profit | 137.03M | 146.24M | 16.06M | 128.11M | 15.36M | 18.49M |
| EBITDA | 33.91M | 44.32M | 31.03M | 27.31M | 32.09M | 31.81M |
| Net Income | 14.19M | 14.00M | 5.70M | 7.13M | 11.35M | 13.86M |
Balance Sheet | ||||||
| Total Assets | 434.70M | 428.90M | 429.80M | 405.25M | 372.04M | 347.62M |
| Cash, Cash Equivalents and Short-Term Investments | 58.20M | 61.60M | 71.14M | 56.20M | 61.68M | 97.13M |
| Total Debt | 150.80M | 146.20M | 161.06M | 145.08M | 114.18M | 112.03M |
| Total Liabilities | 226.90M | 222.60M | 231.79M | 211.95M | 178.61M | 166.29M |
| Stockholders Equity | 207.80M | 206.30M | 198.01M | 193.30M | 193.44M | 181.33M |
Cash Flow | ||||||
| Free Cash Flow | 673.00K | 12.64M | 11.41M | -4.89M | -28.02M | 6.47M |
| Operating Cash Flow | 17.43M | 29.00M | 34.37M | 20.67M | 1.43M | 26.57M |
| Investing Cash Flow | -16.93M | -15.90M | -22.84M | -46.15M | -29.34M | -28.63M |
| Financing Cash Flow | -8.07M | -22.16M | 3.39M | 21.69M | -7.89M | 18.20M |
Lumibird SA Technical Analysis
Negative
25.15
Price Trends
25.75
Negative
25.67
Negative
23.87
Negative
Market Momentum
-0.69
Positive
34.86
Neutral
15.15
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:LBIRD, the sentiment is Negative. The current price of 25.15 is above the 20-day moving average (MA) of 24.78, below the 50-day MA of 25.75, and above the 200-day MA of 23.87, indicating a bearish trend. The MACD of -0.69 indicates Positive momentum. The RSI at 34.86 is Neutral, neither overbought nor oversold. The STOCH value of 15.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:LBIRD.
Lumibird SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | €9.23B | 20.38 | 11.01% | 1.22% | -3.18% | 22.52% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | €20.44B | 71.46 | 7.11% | 0.32% | 3.76% | 29.94% | |
52 Neutral | €519.28M | 36.90 | 6.85% | 1.59% | 8.13% | 31.36% | |
51 Neutral | €48.55M | -6.28 | 453.10% | ― | -16.98% | 20.31% | |
45 Neutral | €23.43M | 6.26 | -58.93% | ― | 7.43% | ― | |
43 Neutral | €158.55M | -2.91 | 90.10% | ― | 1.79% | 15.89% |
* General Sector Average
FR:LBIRD
Lumibird SA
23.25
3.27
16.38%
FR:BIM
bioMerieux
80.10
-30.68
-27.69%
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.13
0.04
39.56%
FR:DIM
Sartorius Stedim Biotech
215.80
23.58
12.27%
FR:ALTHE
Theraclion SA
0.65
<0.01
0.31%
FR:ALMDT
Median Technologies
3.35
0.11
3.40%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.